The Australian Centre for HIV and Hepatitis Virology Research (ACH2) supports virology and immunology research projects that clearly address the research priorities of the National Hepatitis B Strategy 2010-2013, Third National Hepatitis C Strategy, 2010-2013 and the Sixth National HIV Strategy 2010-2013.

Therefore, research projects aimed at developing vaccine candidates, anti-viral drug targets, novel diagnostics and prognostics for HIV, HBV or HCV, molecular tools for tracking epidemics caused by these organisms, new tests for supporting vaccine and antiviral trials will be supported. Applications not supported include those: not dealing primarily with HIV, hepatitis B or hepatitis C itself – notably those focussed primarily on complications of the disease, such as hepatocellular carcinoma or glomerulonephritis associated with hepatitis C infection; or such as lymphoma, cardiovascular disease, or opportunistic infections associated with HIV infection.

Research projects based on clinical data and specimens from patients with HIV or HCV stored by the Immunovirology Research Network (IVRN) are encouraged. These projects include samples from the STEAL study (evaluating antiretroviral therapy in patients with HIV) and the ATAHC study (evaluating the natural history and efficacy of antiviral treatment in primary Hepatitis C infection), as well as HIV/HBV and HIV/HCV co-infection cohorts.   

The grants are intended to complement and translate basic research in the virology and immunology of HIV, HBV and HCV that are already funded by other granting bodies.